ADPT
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature\'s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Adaptive Biotechnologies Corporation (ADPT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (2.9) | C (2.4) | C+ (2.5) | A- (4.1) | C+ (2.6) | B- (2.9) |
| 2026-11-10 | B- (2.9) | D+ (1.6) | C+ (2.5) | A (4.2) | C+ (2.6) | C+ (2.8) |
| 2026-11-03 | B- (2.9) | B- (3.1) | C+ (2.5) | A- (4.0) | C+ (2.7) | B- (3.1) |
| 2026-10-27 | B- (2.9) | B- (3.1) | C+ (2.5) | A (4.2) | C+ (2.6) | B- (3.1) |
| 2026-10-20 | B- (2.9) | B- (3.1) | C+ (2.5) | A- (3.9) | C+ (2.6) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe